Skip to main content

Blue Cross and Blue Shield of Illinois to Cover CombiMatrix's Services

NEW YORK (GenomeWeb) – CombiMatrix announced today that it has entered into a contract with Blue Cross and Blue Shield of Illinois, the largest health plan in the state. Under the deal, BCBSIL members will have access to CombiMatrix's menu of CombiSNP microarray-based diagnostic testing services for developmental disorders and oncology.

CombiMatrix CEO Mark McDonough in a statement called the BCBSIL deal a "significant benefit to us as we continue to invest in this territory." He noted that Irvine, Calif.-based CombiMatrix recently expanded its sales and marketing presence in the Midwest and has seen increased sales activity as a result.

CombiMatrix has announced agreements with a number of organizations to expand access to its services this year. In July, Atlanta-based preferred provider organization network Stratose said it would cover CombiMatrix's suite of tests. In March, CombiMatrix partnered with American Pathology Partners to offer its microarray-based miscarriage testing service. And in January, it contracted with Galaxy Health Network to provide coverage of its tests for Galaxy's 3.5 million covered lives.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.